Durability of clinical and immunologic responses to extended low-dose interleukin-2 therapy in patients with refractory chronic graft-versus-host disease
暂无分享,去创建一个
J. Ritz | J. Whangbo | Haesook T. Kim | C. Reynolds | J. Koreth | Verónica Donato | Peter Stowe | Carol G. Reynolds
[1] J. Ritz,et al. Organ-specific response after low-dose interleukin-2 therapy for steroid-refractory chronic graft-versus-host disease , 2022, Blood advances.
[2] Stephanie J. Lee,et al. Three FDA-approved therapies for chronic GVHD. , 2022, Blood.
[3] J. Ritz,et al. Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children. , 2019, Blood advances.
[4] J. Ritz,et al. Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease. , 2019, Blood advances.
[5] J. Ritz,et al. Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease. , 2019, Blood advances.
[6] B. Blazar,et al. Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets. , 2017, The New England journal of medicine.
[7] J. Ritz,et al. Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. , 2016, Blood.
[8] J. Ritz,et al. Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD. , 2016, Blood.
[9] B. Sandmaier,et al. Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease. , 2013, Blood.
[10] J. Ritz,et al. Low-Dose Interleukin-2 Therapy Restores Regulatory T Cell Homeostasis in Patients with Chronic Graft-Versus-Host Disease , 2013, Science Translational Medicine.
[11] B. Sandmaier,et al. Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease. , 2013, Blood.
[12] J. Ritz,et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. , 2011, The New England journal of medicine.
[13] B. Kurland,et al. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. , 2011, Blood.
[14] J. Ritz,et al. Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. , 2010, The Journal of clinical investigation.
[15] K. Baird,et al. Chronic graft-versus-host disease (GVHD) in children. , 2010, Pediatric clinics of North America.
[16] E. Shevach. Mechanisms of foxp3+ T regulatory cell-mediated suppression. , 2009, Immunity.
[17] J. Ritz,et al. Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. , 2005, Blood.
[18] R. Storb,et al. Duration of immunosuppressive treatment for chronic graft-versus-host disease. , 2004, Blood.
[19] T. Malek,et al. Tolerance, not immunity, crucially depends on IL-2 , 2004, Nature Reviews Immunology.
[20] B. Nelson. IL-2, Regulatory T Cells, and Tolerance , 2004, The Journal of Immunology.
[21] M. Toda,et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. , 1995, Journal of immunology.